Abemaciclib plus endocrine therapy: A new hope for high-risk early breast cancer?
06 Nov 2020
byRoshini Claire Anthony
Adding abemaciclib to adjuvant endocrine therapy (ET) resulted in improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in women with hormone receptor (HR)+, HER2-negative, node-positive early breast cancer at high risk of recurrence, results of the phase III monarchE* trial showed.